US EditionUK finalises US pharma deal granting tariff-free access for British medicines
The deal gives UK drugmakers three years of tariff-free access while Britain agrees to higher NHS prices and spending on new medicines.
- On Thursday, British Business and Trade Secretary Peter Kyle announced a finalized pharmaceutical trade deal with the United States, securing zero tariffs on UK-made medicines for at least three years.
- Britain agreed to raise the net price paid by the National Health Service for new medicines by 25% starting April 2026, a move intended to secure tariff-free access to American markets.
- The arrangement requires changes to the appraisal framework at NICE, with tariff exemptions conditional on major UK pharmaceutical companies complying with separate U.S. government pricing agreements.
- U.S. Trade Representative Jamieson Greer said President Donald Trump seeks to ensure trading partners pay their "fair share" for innovative medicines, while the administration warned of 100% tariffs on imports failing to meet pricing demands.
- AstraZeneca and GSK previously secured "most favoured nation" pricing deals with the administration, while closer cooperation between British and U.S. regulators will align medical device standards and accelerate technology access.
14 Articles
14 Articles
UK and US Finalize Groundbreaking Tariff-Free Pharma Trade Deal
The UK has secured a landmark pharmaceutical trade agreement with the U.S., granting tariff-free export of UK medicines in exchange for increased prices on new drugs. This deal fortifies Britain's pharmaceutical foothold in the U.S. market while enhancing cooperation between healthcare regulatory bodies.
expert reaction to US-UK pharmaceutical partnership
Nicola Perrin, Chief Executive, Association of Medical Research Charities, said: “For our member charities, the worst possible scenario is having a discovery stuck in the lab, or a treatment available in other countries but not through the NHS. We therefore welcome today’s announcement and the progress that has been made since last December. This reinforces the Government’s commitment to making the UK one of the best places in the world to dev…
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
